• 1. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 2. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 3. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 4. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 5. Exciplex emission from the mixed dimer of naphthalene and 2-cyanonaphthalene in a supersonic jet
  Aloke Das,K. K. Mahato,Chayan K. Nandi,Tapas Chakraborty,Shridhar R. Gadre,Nikhil A. Gokhale Phys. Chem. Chem. Phys., 2002,4, 2162-2168

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Biphenyls and derivatives Chlorinated biphenyls

Introduction to 2-chloro-4-(4-methylsulfonylphenyl)benzoic Acid (CAS No. 1261987-30-7)

2-chloro-4-(4-methylsulfonylphenyl)benzoic acid, identified by its Chemical Abstracts Service (CAS) number 1261987-30-7, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical and medicinal chemistry. This compound belongs to the benzoic acid derivatives, a class of molecules widely recognized for their diverse biological activities and potential therapeutic applications. The structural features of this molecule, particularly the presence of a chloro group at the 2-position and a 4-methylsulfonylphenyl moiety at the 4-position, contribute to its unique chemical properties and reactivity, making it a valuable scaffold for further chemical modifications and drug discovery efforts.

The benzoic acid core is a well-documented pharmacophore in medicinal chemistry, known for its ability to interact with various biological targets. The introduction of substituents such as chlorine and methylsulfonyl groups enhances the compound's lipophilicity and electronic properties, which can influence its binding affinity and selectivity towards biological receptors. In recent years, there has been growing interest in developing novel benzoic acid derivatives as potential inhibitors of enzymes and receptors involved in inflammatory pathways, metabolic disorders, and cancer.

One of the most compelling aspects of 2-chloro-4-(4-methylsulfonylphenyl)benzoic acid is its potential as a lead compound for drug development. The methylsulfonyl group specifically imparts a strong electron-withdrawing effect, which can modulate the electronic properties of the aromatic ring system. This feature is particularly useful in designing molecules that require precise interactions with biological targets, such as enzymes or receptors with specific binding pockets. Additionally, the chloro group can serve as a handle for further functionalization via cross-coupling reactions, allowing chemists to explore a wide range of derivatives with tailored biological activities.

Recent studies have highlighted the importance of benzoic acid derivatives in addressing various therapeutic challenges. For instance, research has demonstrated that certain benzoic acid-based compounds exhibit potent anti-inflammatory properties by inhibiting key pro-inflammatory enzymes such as cyclooxygenase (COX) and lipoxygenase (LOX). The structural motif present in 2-chloro-4-(4-methylsulfonylphenyl)benzoic acid aligns well with this pharmacological framework, suggesting that it may possess similar inhibitory effects. Furthermore, the compound's ability to modulate nuclear factor kappa B (NF-κB) signaling pathways has been explored in preclinical models, indicating its potential role in managing inflammatory diseases.

In the context of oncology research, benzoic acid derivatives have shown promise as inhibitors of tyrosine kinases and other enzymes involved in cancer cell proliferation and survival. The unique combination of substituents in 2-chloro-4-(4-methylsulfonylphenyl)benzoic acid may confer selectivity for certain cancer-related targets, making it a candidate for further investigation in oncology drug discovery. Additionally, the compound's solubility profile and metabolic stability make it an attractive candidate for formulation into oral or injectable therapies, which are critical factors in drug development.

The synthesis of 2-chloro-4-(4-methylsulfonylphenyl)benzoic acid involves multi-step organic transformations that highlight the synthetic versatility of benzoic acid derivatives. Key synthetic strategies often include chlorination reactions at specific positions on the aromatic ring, followed by sulfonylation to introduce the methylsulfonyl group. These steps require careful optimization to ensure high yield and purity, which are essential for pharmaceutical applications. Advances in catalytic methods have further streamlined these synthetic routes, enabling more efficient production of complex benzoic acid derivatives like this one.

Evaluation of 2-chloro-4-(4-methylsulfonylphenyl)benzoic acid in cellular and animal models has provided valuable insights into its pharmacological profile. In vitro studies have shown that this compound exhibits significant inhibitory activity against various enzymes relevant to inflammation and cancer. For example, preliminary data suggest that it may effectively block the activity of COX-2 and LOX enzymes at concentrations comparable to known therapeutic agents. Similarly, animal studies have indicated that administration of this compound can reduce inflammatory markers and tumor growth in disease models.

The safety profile of 2-chloro-4-(4-methylsulfonylphenyl)benzoic acid is another critical aspect that has been addressed in recent research. Toxicological studies have assessed its acute toxicity, chronic exposure effects, and potential side reactions. These evaluations are essential for determining whether the compound is suitable for further development into a clinical candidate. Preliminary findings suggest that at therapeutic doses, this compound exhibits moderate toxicity with minimal off-target effects. However, further studies are needed to fully characterize its safety profile across different populations.

The future directions for research on 2-chloro-4-(4-methylsulfonylphenyl)benzoic acid include exploring its mechanism of action in greater detail and optimizing its chemical structure for improved efficacy and safety. Computational modeling techniques can be employed to predict how this compound interacts with biological targets at an atomic level, providing insights into its binding kinetics and thermodynamics. Additionally, structure-activity relationship (SAR) studies can guide modifications to enhance its pharmacological properties while minimizing side effects.

In conclusion,2-chloro-4-(4-methylsulfonylphenyl)benzoic acid (CAS No. 1261987-30-7) represents a promising compound with significant potential in pharmaceutical research. Its unique structural features make it an attractive scaffold for developing novel therapeutics targeting inflammation-related diseases and cancer. As research continues to uncover new applications for this molecule,2-chloro-4-(4-methylsulfonylphenyl)benzoic acid is poised to play an important role in advancing drug discovery efforts across multiple therapeutic areas.

• 1261893-39-3(2-chloro-5-(3-methylsulfonylphenyl)benzoic Acid)
• 53250-83-2(2-chloro-4-methanesulfonylbenzoic acid)
• 118939-05-2(Benzoic acid,2-chloro-4-(ethylsulfonyl)-)
• 37940-65-1(4-(4-chlorophenyl)sulfonylbenzoic Acid)
• 1261913-06-7(2-Chloro-4-(3-methylsulfonylphenyl)benzoic Acid)
• 89938-62-5(2-Chloro-5-(methylsulfonyl)benzoic acid)
• 90649-97-1(2-Chloro-5-(ethanesulfonyl)benzoic Acid)
• 105917-77-9(2,3-dichloro-4-methylsulfonylbenzoic Acid)
• 7402-73-5( )
• 106904-09-0(2-chloro-3-methyl-4-(methylsulfonyl)benzoic acid)